Psychiatric Services
Journal Home Search Current Issue Past Issues Subscribe All APPI Journals Help Contact Us
 
Psychiatr Serv 58:746-748, June 2007
doi: 10.1176/appi.ps.58.6.746
© 2007 American Psychiatric Association
Quicksearch
Advanced Search
Or Search All APPI Journals
This Article
* Full Text
* Full Text (PDF)
* Alert me when this article is cited
* Alert me if a correction is posted
* Citation Map
Services
* Email this article to a Colleague
* Similar articles in this journal
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via Google Scholar
Google Scholar
* Articles by Carey, T. S.
* Articles by Goodman, F.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by Carey, T. S.
* Articles by Goodman, F.
Related Collections
* Quality of Care, Practice Guidelines
* Research Design, Methodology
* Other Somatic Therapy
*Related Article

Column

Best Practices: Comparing Medication Treatments in Mental Health: Drug Class Reviews and Policy Challenges

Timothy S. Carey, M.D., M.P.H., John W. Williams, Jr., M.D., M.H.Sc., Cathy Melvin, Ph.D., John Oldham, M.D., M.S. and Francine Goodman, Pharm.D., B.C.P.S.

Advances in the number and type of medications for psychiatric illness have substantially aided physicians. However, as the number of available medications within a class increases, so does the complexity in decision making for provider and patient. Systematic review of a class of medications can assist providers in drug choice. The purpose and methods of such drug class reviews are described. Critical elements of a quality review include the choice of the question, explicit eligibility criteria, systematic search of the literature, article abstraction, and sometimes pooling of the data by using meta-analysis with direct or indirect comparison of study findings. Best practices are suggested for clinicians, administrators, and policy makers to consider when using drug class reviews in clinical organizations. The number of drug class reviews is increasing, and they have the potential to significantly assist providers, patients, and payers.


Related Article:

June 2007: This Month's Highlights
Psychiatr Serv 2007 58: 739. [Full Text] [PDF]






Get information about faster international access.

Privacy Policy

Copyright © 2007 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us

American Psychiatric Publishing, Inc. American Psychiatric Association
1000 Wilson Boulevard, Suite 1825, Arlington, VA 22209-3901 * 800-368-5777 * appi at psych.org